Jolene J. Bierly
Research Subjects
Research Interests
Jolene J. Bierly has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Amanda L D’ORazio
NMS Labs , Horsham, PA 19044
1 shared publication - Ayako Chan-Hosokawa
NMS Labs , Horsham, PA 19044
1 shared publication Ayako Chan‐Hosokawa
NMS Labs Horsham Pennsylvania USA
1 shared publication- Barry K. Logan
Center for Forensic Science Research and Education Fredric Rieders Family Foundation Horsham Pennsylvania USA
1 shared publication Brianna L. Peterson
NMS Labs, 200 Welsh Rd, Horsham, PA, USA
1 shared publication- Donna M. Papsun
NMS Labs , Horsham, PA 19044
1 shared publication
Latest Publications
- 6 January 2026
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 50 (3)
4-Anilino- N -phenylethylpiperidine (4-ANPP): the potential caution flag for illicit fentanyl
The ability to distinguish illicit fentanyl use is becoming increasingly critical in toxicological investigations. 4-Anilino-N-phenylethylpiperidine (4-ANPP), also known as despropionylfentanyl, is both a precursor in illicit fentanyl production and a minor metabolite frequently detected alongside fentanyl in forensic toxicology. Its presence may assist in distinguishing medical and illicit fentanyl sources. This study evaluated 4-ANPP concentrations and 4-ANPP: fentanyl (4-ANPP to fentanyl) ratios in clinical (presumed medicinal) and postmortem (forensic) submissions to ascertain trends that may aid in source attribution and toxicological interpretation. Blood and serum/plasma (s/p) samples were analyzed via liquid-liquid extraction followed by liquid chromatography tandem mass spectrometry (LC–MS/MS) throughout 2023. A total of 32 723 forensic and 1015 clinical cases positive for fentanyl were included in the analysis. Most clinical 4-ANPP concentrations (69%) were below 0.50 ng/mL, compared to 20% of forensic cases. Forensic blood samples with reportable 4-ANPP concentrations (n = 29 701) had a median of 2.1 ng/mL (mean ± SD: 6.5 ± 42 ng/mL, range: 0.20–4100 ng/mL). In clinical serum/plasma samples with reportable 4-ANPP (n = 451), the median was 0.96 ng/mL (mean ± SD: 3.9 ± 17 ng/mL, range: 0.20–306 ng/mL). In cases with reportable 4-ANPP concentrations, the median 4-ANPP: fentanyl ratio was 0.141 (mean ± SD: 0.22 ± 0.95; range: 0.000078–140) for forensic, while the clinical median was 0.105 (mean ± SD: 0.44 ± 3.0; range: 0.005–60). Notably, 91% of forensic cases had reportable 4-ANPP concentrations (≥0.20 ng/mL) compared to 44% of clinical cases, excluding more than half of the clinical cases from ratio calculations. Although overlapping 4-ANPP: fentanyl ratios limit its utility as a clear indicator of illicit fentanyl use, elevated 4-ANPP concentrations are more strongly associated with non-pharmaceutical sources and may serve as valuable support in forensic interpretation.
- 6 January 2026
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 50 (3)
4-Anilino- N -phenylethylpiperidine (4-ANPP): the potential caution flag for illicit fentanyl
The ability to distinguish illicit fentanyl use is becoming increasingly critical in toxicological investigations. 4-Anilino-N-phenylethylpiperidine (4-ANPP), also known as despropionylfentanyl, is both a precursor in illicit fentanyl production and a minor metabolite frequently detected alongside fentanyl in forensic toxicology. Its presence may assist in distinguishing medical and illicit fentanyl sources. This study evaluated 4-ANPP concentrations and 4-ANPP: fentanyl (4-ANPP to fentanyl) ratios in clinical (presumed medicinal) and postmortem (forensic) submissions to ascertain trends that may aid in source attribution and toxicological interpretation. Blood and serum/plasma (s/p) samples were analyzed via liquid-liquid extraction followed by liquid chromatography tandem mass spectrometry (LC–MS/MS) throughout 2023. A total of 32 723 forensic and 1015 clinical cases positive for fentanyl were included in the analysis. Most clinical 4-ANPP concentrations (69%) were below 0.50 ng/mL, compared to 20% of forensic cases. Forensic blood samples with reportable 4-ANPP concentrations (n = 29 701) had a median of 2.1 ng/mL (mean ± SD: 6.5 ± 42 ng/mL, range: 0.20–4100 ng/mL). In clinical serum/plasma samples with reportable 4-ANPP (n = 451), the median was 0.96 ng/mL (mean ± SD: 3.9 ± 17 ng/mL, range: 0.20–306 ng/mL). In cases with reportable 4-ANPP concentrations, the median 4-ANPP: fentanyl ratio was 0.141 (mean ± SD: 0.22 ± 0.95; range: 0.000078–140) for forensic, while the clinical median was 0.105 (mean ± SD: 0.44 ± 3.0; range: 0.005–60). Notably, 91% of forensic cases had reportable 4-ANPP concentrations (≥0.20 ng/mL) compared to 44% of clinical cases, excluding more than half of the clinical cases from ratio calculations. Although overlapping 4-ANPP: fentanyl ratios limit its utility as a clear indicator of illicit fentanyl use, elevated 4-ANPP concentrations are more strongly associated with non-pharmaceutical sources and may serve as valuable support in forensic interpretation.
- 19 December 2025
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 50 (3)
The rise of nitrous oxide in toxicological casework: no laughing matter
Nitrous oxide (N2O), the colorless, odorless gas known as “laughing gas,” has gained recent attention for its misuse as a recreational drug. As an anesthetic, N2O produces sedation, euphoric, and possible hallucinogenic effects. Adverse effects may include disorientation, psychomotor retardation, hypoxia, and asphyxia. N2O misuse has grown due to its ease of availability, rapid onset of effects, and increased social media attention, leading to anticipated increases in forensic testing needs. Due to its short half-life and volatility, analytical detection can be challenging. From January 2022 through September 2025, over 1700 cases were analyzed for N2O using headspace-gas chromatography–mass spectrometry (HS-GC–MS) over a calibration range of 1.8–180 mcg/mL. Total test requests and percent positivity increased during this timeframe for both driving (DUID) and postmortem (PM)/clinical casework. Blood, brain, liver, lung, and urine yielded positive detections. Attempts at repeat testing indicate significant losses in analyte concentrations. Consideration of pre-analytical and analytical factors is critical for suspected inhalant casework. Overwhelmingly, both DUID and PM casework noted N2O canisters present at the scene. Common driver behaviors included disorientation, slow reaction times, struggling with speech, inability to follow directions, and difficulty maintaining balance. DUID blood draws should be collected as close as possible to the suspected incident. Further review of case histories and testing practices generated handling recommendations for suspected inhalant case samples: fill containers to limit headspace; glass containers and tight-fitted closures are preferred; avoid transferring volume to alternate containers; limit container ingresses; and avoid repeat testing within the same container. Multiple matrices/containers should be collected and preserved, whenever possible, with inhalant testing prioritized over other drugs and/or alcohol. Laboratories should also consider qualitative reporting and/or testing as a one-time analysis. By employing these best practices, an inhalant gas may be better collected and preserved, increasing the chances of detection.
- 19 December 2025
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 50 (3)
The rise of nitrous oxide in toxicological casework: no laughing matter
Nitrous oxide (N2O), the colorless, odorless gas known as “laughing gas,” has gained recent attention for its misuse as a recreational drug. As an anesthetic, N2O produces sedation, euphoric, and possible hallucinogenic effects. Adverse effects may include disorientation, psychomotor retardation, hypoxia, and asphyxia. N2O misuse has grown due to its ease of availability, rapid onset of effects, and increased social media attention, leading to anticipated increases in forensic testing needs. Due to its short half-life and volatility, analytical detection can be challenging. From January 2022 through September 2025, over 1700 cases were analyzed for N2O using headspace-gas chromatography–mass spectrometry (HS-GC–MS) over a calibration range of 1.8–180 mcg/mL. Total test requests and percent positivity increased during this timeframe for both driving (DUID) and postmortem (PM)/clinical casework. Blood, brain, liver, lung, and urine yielded positive detections. Attempts at repeat testing indicate significant losses in analyte concentrations. Consideration of pre-analytical and analytical factors is critical for suspected inhalant casework. Overwhelmingly, both DUID and PM casework noted N2O canisters present at the scene. Common driver behaviors included disorientation, slow reaction times, struggling with speech, inability to follow directions, and difficulty maintaining balance. DUID blood draws should be collected as close as possible to the suspected incident. Further review of case histories and testing practices generated handling recommendations for suspected inhalant case samples: fill containers to limit headspace; glass containers and tight-fitted closures are preferred; avoid transferring volume to alternate containers; limit container ingresses; and avoid repeat testing within the same container. Multiple matrices/containers should be collected and preserved, whenever possible, with inhalant testing prioritized over other drugs and/or alcohol. Laboratories should also consider qualitative reporting and/or testing as a one-time analysis. By employing these best practices, an inhalant gas may be better collected and preserved, increasing the chances of detection.
- 28 August 2024
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 48 (9) , 653-658
Bromazolam in impaired driving investigations
The designer benzodiazepine bromazolam is increasingly encountered in forensic casework, including impaired driving investigations. A series of suspected impaired driving cases that tested positive for bromazolam are described herein along with information about driving performance, driver appearance, and observed behavior. Bromazolam was indicated in casework either through screening by liquid chromatography–time of flight mass spectrometry (LC–TOF-MS) and/or a positive benzodiazepine immunoassay screen. Blood samples were forwarded for quantitative confirmatory analysis using a liquid chromatography–tandem mass spectrometry (LC–MS–MS) method with a reporting limit of 2.0 ng/mL. Bromazolam was reported in 98 impaired driving cases from samples reported between January 2021 and December 2023, with the earliest detection from September 2020. Mean and median blood concentrations were 125 ± 145 and 84 ng/mL respectively, with a range of 4.2–990 ng/mL. Additional positive findings were reported in almost all cases, with the highest result (990 ng/mL) being the only case in which bromazolam was the only finding. Fentanyl was the most frequent drug found in combination with bromazolam. Driving behaviors reported in these cases included erratic driving, errors in Standardized Field Sobriety Tests, and symptoms consistent with central nervous system depressants, including slurred speech, incoordination, and lethargic behavior. Based on its prevalence and demonstrated impairing effects, bromazolam should be included in the scope of impaired driving testing as long as it continues to be prevalent in the drug supply.
- 28 August 2024
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 48 (9) , 653-658
Bromazolam in impaired driving investigations
The designer benzodiazepine bromazolam is increasingly encountered in forensic casework, including impaired driving investigations. A series of suspected impaired driving cases that tested positive for bromazolam are described herein along with information about driving performance, driver appearance, and observed behavior. Bromazolam was indicated in casework either through screening by liquid chromatography–time of flight mass spectrometry (LC–TOF-MS) and/or a positive benzodiazepine immunoassay screen. Blood samples were forwarded for quantitative confirmatory analysis using a liquid chromatography–tandem mass spectrometry (LC–MS–MS) method with a reporting limit of 2.0 ng/mL. Bromazolam was reported in 98 impaired driving cases from samples reported between January 2021 and December 2023, with the earliest detection from September 2020. Mean and median blood concentrations were 125 ± 145 and 84 ng/mL respectively, with a range of 4.2–990 ng/mL. Additional positive findings were reported in almost all cases, with the highest result (990 ng/mL) being the only case in which bromazolam was the only finding. Fentanyl was the most frequent drug found in combination with bromazolam. Driving behaviors reported in these cases included erratic driving, errors in Standardized Field Sobriety Tests, and symptoms consistent with central nervous system depressants, including slurred speech, incoordination, and lethargic behavior. Based on its prevalence and demonstrated impairing effects, bromazolam should be included in the scope of impaired driving testing as long as it continues to be prevalent in the drug supply.
- 25 February 2024
- Published by Wiley in Journal of Forensic Sciences
- Vol. 69 (3) , 986-992
Gabapentin in drugged driving investigations
The increasing use and misuse of gabapentin pose a major risk to public health and traffic safety. Gabapentin has been approved by the Food and Drug Administration (FDA) since 1993 for adjunctive therapy in the treatment of epilepsy and neuralgia but is increasingly being prescribed for numerous off‐label uses including insomnia, anxiety, depression, and migraine. Reported side effects include blurred vision, drowsiness, and loss of coordination. Driving behaviors such as exiting the lane of travel and crashes have been reported in connection to drugged driving investigations concerning gabapentin. To further assist with the toxicological interpretation of gabapentin in driving under the influence of drugs (DUID) scenarios, a review of approximately 108,000 gabapentin‐positive DUID cases was conducted. Of those, 858 cases met inclusion criteria and underwent additional evaluation. Blood specimens were screened via enzyme‐linked immunosorbent assay (ELISA) and confirmed by liquid chromatography tandem mass spectrometry (LC–MS/MS) for quantitation of gabapentin. This review found an overall DUID gabapentin positivity of 7.9% between January 2020 and December 2022; 17 states from various geographical regions had at least one positive gabapentin DUID case. Observations in six driving and human performance cases where gabapentin was the only drug reported were consistent with the known adverse effects of the medication. Half of the case histories reviewed involved crashes where the driver was determined to be at fault. Additionally, 94% of the cases in this review involved gabapentin in combination with other drugs. The most prevalent drug combinations were opioids and gabapentin present in 64% of cases.
- 25 February 2024
- Published by Wiley in Journal of Forensic Sciences
- Vol. 69 (3) , 986-992
Gabapentin in drugged driving investigations
The increasing use and misuse of gabapentin pose a major risk to public health and traffic safety. Gabapentin has been approved by the Food and Drug Administration (FDA) since 1993 for adjunctive therapy in the treatment of epilepsy and neuralgia but is increasingly being prescribed for numerous off‐label uses including insomnia, anxiety, depression, and migraine. Reported side effects include blurred vision, drowsiness, and loss of coordination. Driving behaviors such as exiting the lane of travel and crashes have been reported in connection to drugged driving investigations concerning gabapentin. To further assist with the toxicological interpretation of gabapentin in driving under the influence of drugs (DUID) scenarios, a review of approximately 108,000 gabapentin‐positive DUID cases was conducted. Of those, 858 cases met inclusion criteria and underwent additional evaluation. Blood specimens were screened via enzyme‐linked immunosorbent assay (ELISA) and confirmed by liquid chromatography tandem mass spectrometry (LC–MS/MS) for quantitation of gabapentin. This review found an overall DUID gabapentin positivity of 7.9% between January 2020 and December 2022; 17 states from various geographical regions had at least one positive gabapentin DUID case. Observations in six driving and human performance cases where gabapentin was the only drug reported were consistent with the known adverse effects of the medication. Half of the case histories reviewed involved crashes where the driver was determined to be at fault. Additionally, 94% of the cases in this review involved gabapentin in combination with other drugs. The most prevalent drug combinations were opioids and gabapentin present in 64% of cases.
- 28 November 2023
- Published by Elsevier in Journal of Forensic and Legal Medicine
- Vol. 101, 102625
Distribution of donepezil in postmortem casework
- 28 November 2023
- Published by Elsevier in Journal of Forensic and Legal Medicine
- Vol. 101, 102625
Distribution of donepezil in postmortem casework